In summary, our study provides the evidence that MA treatment could alleviate MI/RI through suppressing both the inflammation and apoptosis in a dose-dependent manner, and the cardioprotective effect of MA may be partly attributable to the inactivation of HMGB1/TLR4/NF-κB pathway. The gene discussed is TLR4; the disease is myocardial infarction.